-
公开(公告)号：US20210401971A1
公开(公告)日：2021-12-30
申请号：US17467632
申请日：2021-09-07
申请人： CureVac AG
发明人： Susanne RAUCH
IPC分类号： A61K39/215 , C07K14/165 , C12N15/86
摘要： The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
-
公开(公告)号：US20210401966A1
公开(公告)日：2021-12-30
申请号：US17469313
申请日：2021-09-08
申请人： CureVac AG
IPC分类号： A61K39/125 , C07K14/005 , A61P31/12 , A61K9/00
摘要： The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
-
公开(公告)号：US20220211838A1
公开(公告)日：2022-07-07
申请号：US17665704
申请日：2022-02-07
申请人： CureVac AG
IPC分类号： A61K39/145 , A61K39/155 , C07K14/005 , C12N7/00
摘要： The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.
-
公开(公告)号：US20220202930A1
公开(公告)日：2022-06-30
申请号：US17558257
申请日：2021-12-21
摘要： The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
-
公开(公告)号：US20180312545A1
公开(公告)日：2018-11-01
申请号：US15774423
申请日：2016-11-09
申请人： CureVac AG
发明人： Patrick BAUMHOF , Susanne RAUCH , Aleksandra KOWALCZYK , Johannes LUTZ , Edith JASNY , Benjamin PETSCH , Andreas THESS , Thomas SCHLAKE , Mariola FOTIN-MLECZEK , Regina HEIDENREICH , Sandra LAZZARO , Fatma DÖNER , Wolfgang GROSSE
IPC分类号： C07K14/005 , C07K14/205 , A61K39/145
CPC分类号： C12N15/00 , A61K39/12 , A61K2039/53 , C07K14/005 , C07K2319/00 , C12N2760/16122 , C12N2760/16134
摘要： The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.
-
公开(公告)号：US20220313813A1
公开(公告)日：2022-10-06
申请号：US17620047
申请日：2020-06-18
申请人： CureVac AG
发明人： Susanne RAUCH , Sandro ROIER , Benjamin PETSCH
IPC分类号： A61K39/15 , C12N7/00 , C07K14/005 , A61K39/145 , A61P31/14
摘要： The invention is directed to a coding RNA for a Rotavirus vaccine. The coding RNA comprises at least one coding region encoding at least one antigenic peptide or protein of a Rotavirus, in particular VPS* of a Rotavirus, or immunogenic fragment or immunogenic variant thereof. The present invention is also directed to compositions and vaccines comprising said coding RNA in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). Further, the invention concerns a kit, particularly a kit of parts comprising the coding RNA, or the composition, or the vaccine. The invention is also directed to a kit or kit of parts, medical treatments, and the first and second medical uses.
-
公开(公告)号：US20210361761A1
公开(公告)日：2021-11-25
申请号：US17045236
申请日：2019-04-05
申请人： CureVac AG
摘要： The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with yellow fewer vims (YFV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.
-
公开(公告)号：US20210162037A1
公开(公告)日：2021-06-03
申请号：US16098834
申请日：2017-05-04
申请人： CureVac AG
IPC分类号： A61K39/145
摘要： The present invention relates to mRNA sequences usable as mRNA-based vaccines against infections with influenza viruses. Additionally, the present invention relates to a composition comprising the mRNA sequences and the use of the mRNA sequences or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of influenza virus infections. The present invention further describes a method of treatment or prophylaxis of infections with influenza virus using the mRNA sequences.
-
公开(公告)号：US20190125857A1
公开(公告)日：2019-05-02
申请号：US16098840
申请日：2017-05-04
申请人： CureVac AG
IPC分类号： A61K39/125 , A61K9/00 , A61P31/12
摘要： The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
-
公开(公告)号：US20170326225A1
公开(公告)日：2017-11-16
申请号：US15536595
申请日：2015-12-16
申请人： CureVac AG
发明人： Susanne RAUCH , Edith JASNY
IPC分类号： A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
CPC分类号： A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/575 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2760/14134 , C12N2760/14234 , C12N2830/50
摘要： The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Additionally, the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein (GP) and/or the matrix protein 40 (VP40) and/or the nucleoprotein (NP) of a virus of the genus Ebolavirus or Marburgvirus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Ebolavirus or Marburgvirus infections. The present invention further describes a method of treatment or prophylaxis of Ebolavirus or Marburgvirus infections using the mRNA sequence.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.025 秒)
